CD274 and cancer: PD-1/PD-L1 and CTLA-4, each with several clinically approved targeted antibodies, are currently used to treat more than 17 cancers (de Miguel Calvo, 2020) and excel in controlling disease progression, prolonging survival, and improving quality of life (Tartarone et al., 2019; Nishijima et al., 2019; Liu et al., 2020).